Navigation Links
More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy
Date:4/7/2008

e effects such as retrograde ejaculation, decreased libido, and hypotension as well as patients' belief that symptoms will go away on their own are key reasons for the low drug-treatment rate.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field.

-- Qualitative diagnosis/referral/treatment algorithm for the United

States.

-- Drug usage by lines of therapy (1st, 2nd, 3rd line).

-- Discussion of key freeform combinations by lines of therapy.

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line).

-- Progression of therapy from key 1st line products.

-- Pathway to key therapies from previous therapies.

-- Qualitative analysis of two-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

78
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
5. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
10. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
11. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... LLY ) today announced final results from a retrospective ... risk of acute pancreatitis among initiators of BYETTA® (exenatide) ... antidiabetic therapies. These findings were presented at the 70th ...
... N.C. , June 25 Ruedi Waeger , Ph.D., former ... Board of Directors, was honored with the Robert W. Reilly Leadership award ... . , , , ... the Plasma Protein Therapeutics Association (PPTA) and recognizes individuals who exemplify the leadership ...
... , CRANBURY, N.J. , June 25 Palatin ... has entered into definitive agreements with certain accredited investors to sell ... of $0.20 per unit for gross proceeds of ... expenses.  Each unit will consist of one share of common stock ...
Cached Biology Technology:Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 2Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 3Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 4Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 5Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 6Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 7Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 8Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association 2Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering 2Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering 3
(Date:7/9/2014)... Caesarean section have a different intestinal flora than children delivered ... is the case and what it means for the immune ... therefore decided to scrutinise the impact of birth on the ... mouse pups. , The study shows that ... of cells that strengthen the immune system, says Camilla Hartmann ...
(Date:7/9/2014)... switch out one gene for another in a line ... fiction to reality within this decade. As with any ... of fixing disease-causing genes in humans, for example--as well ... put one of those concerns to rest: using gene-editing ... of mutations in the cells. The new results were ...
(Date:7/9/2014)... deer hunts in Indiana state parks have helped restore ... caused by overabundant populations of white-tailed deer, a Purdue ... Jenkins, associate professor of forest ecology, found that a ... hunts in state parks has successfully spurred the regrowth ... by browsing deer. , Jenkins said that while ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2
... 12 surgeons and 21 surgical residents, video game skill ... a simulated surgery skills course, according to a report ... of the JAMA/Archives journals. , James C. Rosser Jr., ... colleagues asked 33 surgeons (21 residents and 12 attending ...
... speculated that lead poisoning may have played a role in ... have been caused by the concentration of grape juice in ... damage to the environment, the annual production of lead continues ... glass, and electronic components. However, there has thus far been ...
... made to retain naturally occurring compounds called flavanols may ... and chart the course for future research that could ... dementia, according to a panel of scientists who presented ... Association for the Advancement of Science (AAAS). , Several ...
Cached Biology News:Lead with a poisonous electron shield 2Flavanols in cocoa may offer benefits to the brain 2Flavanols in cocoa may offer benefits to the brain 3
GlutaMAX-I Supplement...
Chemically Defined Lipid Concentrate...
... Cell Dissociation Buffers are membrane-filtered isotonic ... chelating agents and cell-conditioning agents in ... salt solution or Ca2+- and ... of mammalian cells from support substrates ...
... g Blocking Reagent , 2 x 50 ml 10X ... , 0.2 ml BL21 glycerol stock , 0.2 ... stock , 1010 pfu T7Select Positive Control Lysate , ... l S-protein HRP Conjugate , 2 ml T7Select S-protein ...
Biology Products: